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1. Introduction
The angiotensin II AT1R system is a key regulator of
cardiovascular functions and one of the most important cardio-
vascular drug targets [1,2]. Angiotensin II is released by angioten-
sin-converting enzyme (ACE)-dependent cleavage of angiotensin I,
which is generated from the precursor angiotensinogen by
enzymatic activity of renin [3,4]. Angiotensin II binds to two
different receptors, AT1R and AT2R [5]. Numerous studies
documented that the AT1 receptor is the responsible receptor
involved in cardiovascular pathologies of the vasculature, heart,
kidney and brain [6–9] whereas the pathophysiological role of
AT2R is still under investigation, and drugs targeting AT2R are not
approved for clinical use to date [10,11].
Since its discovery, the bradykinin B2 receptor system
emerged as the physiological antagonist of the angiotensin II
AT1R system by acting as potent vasodepressor [12–14]. Due to
its blood pressure-lowering capacity, activation of the bradykinin
B2 receptor system has long been considered as potential
approach for prevention and treatment of cardiovascular
diseases [15]. But B2R-selective agonists with sufﬁcient in vivo
stability are not yet available and potential side effects are a
concern [16].
Nevertheless, the B2 receptor is an existing cardiovascular drug
target that is activated by the class of ACE-inhibiting drugs. Notably,
beneﬁcial bradykinin B2 receptor activation in vivo is achieved by
application of an ACE inhibitor because the angiotensin-converting
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A B S T R A C T
The AT1 receptor for the vasopressor angiotensin II is one of the most important drug targets for the
treatment of cardiovascular diseases. Sensitization of the AT1 receptor system is a common feature
contributing to the pathogenesis of many cardiovascular disorders but underlying mechanisms are not
fully understood. More than a decade ago, evidence was provided for control of AT1R activation by
heterodimerization with the B2 receptor for the vasodepressor peptide, bradykinin, a physiological
counterpart of the vasoconstrictor angiotensin II. AT1–B2 receptor heterodimerization was shown to
enhance AT1R-stimulated signaling under pathophysiological conditions such as experimental and
human pregnancy hypertension. Notably, AT1R signal sensitization of patients with preeclampsia
hypertension was attributed to AT1R–B2R heterodimerization. Vice versa, transgenic mice lacking the
AT1–B2 receptor heterodimer due to targeted deletion of the B2R gene showed a signiﬁcantly reduced
AT1R-stimulated vasopressor response compared to transgenic mice with abundant AT1R–B2R
heterodimerization. Biophysical methods such as BRET and FRET conﬁrmed those data by demonstrating
efﬁcient AT1–B2 receptor heterodimerization in transfected cells and transgenic mice. Recently, a study
on AT1R-speciﬁc biased agonism directed the focus to the AT1–B2 receptor heterodimer again. The b-
arrestin-biased [Sar1,Ile4,Ile8]-angiotensin II promoted not only the recruitment of b-arrestin to the
AT1R but also stimulated the down-regulation of the AT1R-associated B2 receptor by co-internalization.
Thereby speciﬁc targeting of the AT1R–B2R heterodimer became feasible and could open the way to a
new class of drugs, which speciﬁcally interfere with pathological angiotensin II-AT1 receptor system
activation.
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enzyme not only cleaves angiotensin I to release angiotensin II, but
also executes degradation and inactivation of bradykinin peptides
[17]. Consequently, inhibition of ACE prevents not only the
generation of the vasopressor angiotensin II but also increases the
availability of the vasodepressor peptide bradykinin [17]. Patient
studies with a B2R-selective antagonist conﬁrmed that bradykinin
B2 receptor activation contributes indeed to the blood pressure-
lowering activity of an ACE inhibitor [18].
In light of those discoveries, numerous studies with ACE
inhibitors and AT1 receptor antagonists documented physiological
antagonism between the vasopressor AT1 receptor and the
bradykinin-activated vasodepressor B2 receptor system [19].
The more surprising was the ﬁnding that the vasodepressor B2
receptor protein enhanced signaling of the vasopressor angioten-
sin II AT1 receptor by formation of a heterodimeric receptor
protein complex [20,21]. Signal enhancement of the AT1 receptor
relied solely on the B2R protein and did not require the agonist
bradykinin [20,21]. The concept that the biological role of a
receptor protein was different from the agonist-stimulated
receptor was provocative and is still under discussion [22,23].
However, recent studies supported the existence of AT1R–B2R
heterodimerization by biophysical techniques such as ﬂuorescence
resonance energy transfer, FRET [24], and bioluminescence
resonance energy transfer, BRET [25]. Moreover, speciﬁc targeting
of the functional interaction between those two receptor proteins
by a small molecule compound was approached [25]. The AT1–B2
receptor heterodimer could thus constitute a novel ‘‘druggable’’
target within the renin–angiotensin–aldosterone system, RAAS.
2. The vasopressor angiotensin II AT1 receptor system
The angiotensin II AT1 receptor system was discovered more
than 100 years ago as potent vasopressor-generating cascade [3,4].
Angiotensin II is released from the precursor angiotensinogen after
sequential cleavage with renin and the angiotensin-converting
enzyme, ACE [3]. By stimulation of the AT1 receptor and
subsequent aldosterone release, angiotensin II controls vascular
tone, salt and water homeostasis, cardiomyocyte growth, and
smooth muscle proliferation [6–9]. The available spectrum of
drugs targeting that system encompasses the class of ACE
inhibitors and AT1-speciﬁc receptor antagonists as largest drug
families. Renin–angiotensin–aldosterone system-targeting drugs
also include mineralocorticoid receptor antagonists, which block
aldosterone-mediated effects of RAAS. Finally, the class of renin
inhibitors is the most recent addition of approved drugs modifying
biological functions of the angiotensin II system [26]. Indications of
angiotensin II AT1R-targeting drugs include essential hyperten-
sion, congestive heart failure, ischemic heart disease, atheroscle-
rosis, diabetic nephropathy and cerebrovascular stroke.
Cardioprotection, atheroprotection and renoprotection are key
features of all drugs, which were documented by a wealth of
clinical and experimental studies [1,2]. The pharmacological
proﬁle of angiotensin II-AT1R blockade was extended by recent
observations regarding neuroprotective activities of centrally
active ACE inhibitors and AT1R antagonists, which could be
beneﬁcial in retarding neurodegeneration, memory loss and other
symptoms associated with dementing diseases such as Alzhei-
mer’s disease [27,28].
A panoply of experimental and clinical studies elucidated
pathomechanisms triggered by stimulation of the angiotensin II
AT1 receptor, which could account for beneﬁcial actions of
angiotensin II AT1R-inhibiting drugs. Activation of the AT1
receptor of vascular smooth muscle cells exerts vasoconstriction,
mainly by activation of a classical Gq/11-coupled signal transduc-
tion pathway. In concert with the generation of ROS, AT1R
stimulates cell growth and proliferation, which leads to vascular
hypertrophy and smooth muscle phenotype transformation from
synthetic to proliferative [29,30]. In the heart, signal transduction
pathways stimulated by AT1R promote cardiac hypertrophy,
cardiac ﬁbrosis and lipid overload, culminating ﬁnally in cardio-
myocyte death [31,32]. In addition to vasculature-driven pressure
overload, those pathomechanisms are major contributors to the
pathogenesis of heart failure [33]. In the kidney, AT1R controls
water and sodium retention, directly by stimulating water and
sodium reabsorption in the proximal tubule and indirectly by
stimulating the generation of aldosterone [2,34]. The latter
hormone further acts on mineralocorticoid receptors of the
cardiovascular system and thereby exerts a key role in the
development of heart failure [35]. In addition to peripheral actions,
stimulation of the AT1 receptor in the central nervous system has
an important role in blood pressure control by promoting the
release of sympathetic neurotransmitters such as adrenaline and
noradrenaline, or the stress response-related corticosteroids
[36,37]. By an action on bone marrow progenitor cells, angiotensin
II AT1R activation stimulates lympho- and erythropoiesis [38].
Those effects of the angiotensin AT1R system on bone marrow-
derived and circulating blood cells are considered to contribute to
pro-inﬂammatory responses and the pathogenesis of atheroscle-
rosis [39,40].
3. The bradykinin B2 receptor system – a physiological
antagonist of the angiotensin II AT1 receptor system
Bradykinin and the related peptide kallidin (Lys0-bradykinin)
were discovered as potent vasodepressor peptides, which are
released by proteolytic cleavage of the precursor high-molecular-
weight (HMW) and low-molecular-weight (LMW) kininogen by
the action of kallikrein [12,13,41]. Bradykinin exerts vasorelaxa-
tion and related physiological functions by stimulating the
constitutively expressed B2 receptor [14,42,43]. The vasodepressor
activity is due to the generation of nitric oxide (NO) by endothelial
B2 receptors activating a Gq/11-coupled signal transduction
cascade, and by the release of eicosanoids and EDHF [44]. With
those vasodepressor actions, the bradykinin B2 receptor system is
a physiological antagonist of the angiotensin II AT1R system [16].
At the level of ACE, the angiotensin II and bradykinin systems
are interconnected (Fig. 1). ACE not only generates the vasopressor
angiotensin II but also accounts for the proteolytic degradation of
B2 receptor-stimulating vasodepressor peptides, bradykinin and
Fig. 1. The vasoactive peptide systems for angiotensin II and bradykinin are
interconnected. ACE inhibition blocks the generation of the vasopressor peptide
angiotensin II and reduces the degradation of the vasodepressor bradykinin (green).
Upon AT1R antagonism, bradykinin level could also increase, most likely by AT2
receptor-stimulated kallikrein activation (light yellow).
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kallidin (Fig. 1). Thus, ACE promotes a vasopressor response by
reciprocally controlling the physiological availability of the
antagonistic peptides angiotensin II and bradykinin [16]. Vice
versa, inhibition of ACE by an ACE inhibitor blocks the generation
of angiotensin II and enhances the availability of the vasodepres-
sor, bradykinin (Fig. 1). Studies with the B2R-speciﬁc antagonist
HOE140 (Icatibant) demonstrated that such an effect is relevant in
various models of cardiovascular diseases and patients where B2
receptor stimulation contributes to the blood pressure lowering
activity of ACE inhibitors and the beneﬁcial effect of ischemic
preconditioning [17–19].
In comparison to ACE inhibition, the proﬁle of AT1 receptor
antagonists is different and bradykinin exerts only a minor role
[45]. In agreement with that notion, AT1R antagonists have a
documented lower frequency of potential and proven bradykinin-
mediated side effects such as cough and angioedema [46].
Nevertheless, circulating bradykinin levels were also shown to
increase upon AT1R blockade [47]. That effect could be mediated
by angiotensin II AT2 receptor-mediated bradykinin generation
[48–50]. As a result, the bradykinin B2 receptor could support the
AT2R-dependent NO generation and vasodilation upon AT1R
inhibition, at least in experimental models [51–53]. Taken
together, the bradykinin B2 receptor acts as the physiological
counterpart of the AT1 receptor either directly or in concert with
the AT2 receptor (Fig. 1).
4. Vasopressor meets vasodepressor: the AT1–B2 receptor
heterodimer
4.1. Discovery of AT1–B2 receptor heterodimerization by biochemical
and biophysical methods
In view of the physiological interconnections between
bradykinin B2 receptor-mediated and angiotensin II AT1
receptor-mediated effects, we sought to determine whether
there was a direct interaction between the angiotensin and
bradykinin systems at the level of the receptor proteins. Those
investigations led to the discovery of a physical interaction
between the AT1 and B2 receptor proteins by formation of a high
molecular mass protein complex [20]. The AT1 and B2 receptor
complex was not only detected with AT1–B2 receptor-trans-
fected HEK cells but also with endogenously expressed AT1 and
B2 receptors of aortic smooth muscle cells and omental vessels
by co-immunoenrichment studies [20,21]. According to the
molecular mass of the protein complex stabilized by a cleavable
cross-linker, the complex was identiﬁed as AT1–B2 receptor
heterodimer [20,21].
In 2011, AT1–B2 receptor hetero(di)merization was conﬁrmed
by a biophysical method, using ﬂuorescence resonance energy
transfer (FRET), which detects protein–protein interactions in close
proximity, at a distance of less than 10 nm [24]. The FRET study
applied fusion proteins of the AT1 and B2 receptor, respectively,
with variants of the enhanced green ﬂuorescent protein fused to
the receptor’s C-terminus, i.e. AT1R-Cerulean and B2R-eYFP [24].
The low cell surface delivery of the AT1 receptor-Cerulean fusion
protein was speciﬁcally enhanced by a cleavable signal peptide
attached to the AT1 receptor’s N-terminus [24]. A FRET efﬁciency of
more than 24% indicated that the AT1 receptor and B2 receptor
were in close proximity and formed a complex on the cell
membrane of intact HEK cells [24].
A recent study conﬁrmed those FRET studies and demonstrated
the physical AT1–B2 receptor interaction in intact cells by the
related bioluminescence resonance energy transfer (BRET50)
method using an AT1 receptor tagged at the C-terminus with
Venus ﬂuorescent protein (AT1R-Venus) and a B2 receptor C-
terminally tagged with Renilla luciferase (B2-RLuc) [25].
4.2. Difﬁculties in the detection of AT1–B2 receptor
heterodimerization
Although the initial discovery of AT1–B2 receptor heterodimer
formation seemed straightforward [20,21], several groups failed to
detect AT1–B2 receptor heterodimerization in subsequent years
[22,23]. Reported difﬁculties in the detection of AT1–B2 receptor
heterodimerization in transfected cells under conventional cell
culture conditions [22,23] could be due to the lack of essential
chaperones required for receptor–heterodimer folding [54–56]. In
agreement with that notion, an in vivo cell expansion model was
capable to restore the expression of proteins required for
heterodimer folding, which were susceptible to down-regulation
during in vitro cell cultivation [55]. Apart from AT1R–B2R
heterodimer folding [55], that in vivo cell expansion model has
a documented efﬁcacy to restore other essential proteins of GPCR
signaling pathways as well, which were down-regulated during in
vitro cell culture [57].
In addition to the limited availability of heterodimer-speciﬁc
chaperones, calcium overload-induced apoptosis triggered by
heterodimer-mediated over-stimulation of the Gq/11-signaling
cascade (cf. Section 4.3) could selectively eliminate cells with
abundant AT1–B2 receptor heterodimerization. Likewise, cells
with AT1R–B2R heterodimers are highly susceptible to apoptosis
and/or cell death triggered by angiotensin II/bradykinin derived,
e.g. from culture medium supplemented with serum additive. An
insufﬁcient number of cells with co-expression of AT1R and B2R
results, and could be responsible for the failure to detect AT1R–B2R
heterodimerization and also AT1R–B2R heterodimer-mediated
signaling [22,23]. A deﬁnite conclusion why several groups failed
to detect AT1–B2 receptor heterodimerization, is difﬁcult to draw
because of the lack of precise biochemical and/or histological
control experiments such as co-immunoenrichment studies and/or
(immuno-)ﬂuorescent microscopy of receptor proteins [22,23].
Speciﬁcally, those groups determined the number of receptor
binding sites and inositol phosphate levels with a batch of cells but
did not control for co-expression of AT1R and B2R at the single cell
level [22,23].
Apart from insufﬁcient receptor co-expression, the transiently
transfected AT1 receptor was reported to form constitutive AT1
receptor aggregates under the applied experimental conditions
[22]. Extensive AT1R protein aggregation could also reduce/
prevent the interaction of AT1R with B2R since the balance
between receptor homomerization and heteromerization could be
shifted toward homomers [56]. As an example, the COS cell
transfection system could favor the formation of such homomeric
receptor aggregates, because of a high cellular expression level due
to SV40 large T-antigen-driven DNA replication at high copy
number. Again, control experiments are lacking, such as immuno-
blot detection of receptor proteins to visualize the extent of
receptor protein aggregation and/or immature receptor protein
folding [22,23].
While a deﬁnite answer to the key question why several groups
failed to detect the AT1R–B2R heterodimer cannot be provided due
to lack of essential control experiments, detection of AT1R–B2R
heterodimerization in transfected cells by biochemical and
biophysical methods is feasible, as was demonstrated by different
groups and in different laboratories independently [20,21,24,25].
4.3. The AT1–B2 receptor heterodimer shows enhanced receptor G-
protein activation and altered receptor sequestration
In addition to the sole interaction of two related GPCRs,
experiments with transfected cells also revealed functional differ-
ences between the homomeric AT1 and B2 receptor, respectively,
and the heterodimeric AT1–B2 receptor complex. Notably, the
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formation of the AT1R–B2R complex was accompanied by a
substantial increase in angiotensin II AT1R-stimulated G-protein
activation of Gq/11 and Gi/o proteins. Enhancement of AT1R-
stimulated G-protein activation was independent of bradykinin B2
receptor stimulation because a B2 receptor mutant with a defective
bradykinin-binding site (B2R-F297A) also mediated an enhanced
angiotensin II AT1R response [20]. In contrast, a B2 receptor mutant
with intact bradykinin-binding site but with impaired G-protein
activation due to mutation of the conserved DRY-motif in the
connecting loop of membrane domains III–IV (B2R-Y157A) did not
enhance the AT1R response [20]. Those ﬁndings suggested that a
functional receptor–G-protein interface of the B2 receptor was
required for AT1R signal enhancement by the B2R protein. Such a
characteristic of the AT1R–B2R heterodimer is analogous to the
GABA-B receptor heterodimer, which requires GABA-B1/B2 hetero-
dimerization for efﬁcient G-protein coupling [58]. However, in
contrast to the GABA-B heterodimer, AT1R–B2R heterodimerization
is not a prerequisite for plasma membrane translocation, and
individual AT1 and B2 receptor homomers are also functional.
In addition to the receptor-G-protein interaction, AT1R–B2R
heterodimerization also changed the mode of receptor sequestra-
tion. The sequestration of individual AT1 or B2 receptors,
respectively, was largely dynamin-/clathrin-independent whereas
a dominant-negative dynamin K44A mutant suppressed the
angiotensin II- and/or bradykinin-induced receptor sequestration
of the AT1–B2 receptor heterodimer [20]. This observation
indicated that the intracellular interface of the AT1–B2 receptor
heterodimer was different from that of individual AT1 and B2
receptor homomers. In agreement with altered receptor seques-
tration, angiotensin II stimulation of the AT1–B2 receptor
heterodimer promoted the co-internalization of the B2 receptor
[24]. Vice versa, bradykinin stimulation of the AT1–B2 receptor
heterodimer promoted AT1 receptor co-internalization [24]. These
ﬁndings further conﬁrmed that AT1 and B2 receptors formed a
stable complex on intact cells, which could be activated by
stimulation with angiotensin II or bradykinin. Taken together,
receptor heterodimerization generates a novel receptor entity,
which has clearly distinguished features from the individual AT1
and B2 receptor mono-/homomers regarding G-protein interac-
tion/activation and receptor internalization.
5. Pathophysiological relevance of AT1–B2 receptor
heterodimerization
5.1. The AT1–B2 receptor heterodimer contributes to angiotensin II
hypersensitivity in preeclampsia hypertension
The ﬁnding that heterodimerization enhanced the activation of
the AT1 receptor by angiotensin II, was of major interest in view of
several hypertensive cardiovascular disorders with increased
angiotensin II responsiveness. Notably, preeclampsia hypertension
is characterized by an increased pressor response to angiotensin II
[59–61]. Since preeclampsia/eclampsia is the most common
complication of late pregnancy and still a leading cause of
pregnancy-induced death worldwide, we investigated whether
AT1–B2 receptor heterodimerization was altered in pregnant
women complicated with preeclampsia. We could show that
patients with preeclampsia hypertension had a signiﬁcantly
increased level of AT1–B2 heterodimeric receptors on circulating
blood cells and omental vessels [21]. The ﬁnding that a site-
directed antibody to the connecting loop between membrane
domains III–IV of the B2 receptor was capable to reduce the
angiotensin II AT1R-stimulated G-protein activation on omental
vessels isolated from preeclamptic women, provided strong
evidence for a causal involvement of AT1–B2 receptor hetero-
dimerization in the increased angiotensin II responsiveness and
pressor response of preeclampsia [21,62]. These observations were
the ﬁrst report of altered GPCR dimerization in human disease and
the potential involvement of AT1R–B2R heterodimerization in an
important cardiovascular complication. Nevertheless, the question
is still not solved whether the AT1R–B2R heterodimer could be
used as a basis to develop a preeclampsia-speciﬁc treatment
approach without causing severe developmental defects of the
fetus such as oligohydramnios and renal failure as do other RAAS
inhibitors.
5.2. Increased AT1–B2 receptor heterodimerization in experimental
hypertension
An increased AT1R-stimulated response to the vasopressor
angiotensin II is also a characteristic feature of experimental
models and patients with hypertensive cardiovascular disease
[63–67]. To investigate AT1–B2 receptor heterodimerization in
experimental hypertension, we chose the spontaneously hyper-
tensive rat model. We found an increased level of the AT1–B2
receptor complex on mesangial cells isolated from spontaneously
hypertensive rats compared to normotensive rats [68]. The AT1–B2
receptor heteromeric complex contributed to an enhanced
angiotensin II-stimulated G-protein activation and increased
endothelin-1 secretion of mesangial cells as demonstrated by
the sensitivity of the angiotensin II-stimulated responses to
inhibition by site-directed antibodies against the B2 receptor
intracellular interface [68]. Taken together, increased AT1–B2
receptor heterodimerization is also a characteristic feature of
experimental hypertension and contributes to an enhanced
angiotensin II responsiveness of renal mesangial cells. Since
mesangial cells contribute to the development of hypertension-
induced glomerulosclerosis, those data could suggest the potential
involvement of the AT1–B2 receptor heterodimer in the develop-
ment of hypertensive nephropathy.
6. Decreased AT1R-stimulated vasopressor response in mice
lacking the AT1–B2 receptor heterodimer due to targeted
deletion of the B2 receptor gene
To analyze the impact of the B2 receptor on the angiotensin II
AT1R-stimulated vasopressor response in vivo, B2 receptor-deﬁcient
mice with targeted deletion of the Bdkrb2 gene were applied [43]. To
obtain a control strain with identical genetic background as Bdkrb2/
mice, we restored the constitutive expression of the ubiquitously
expressed B2 receptor in Bdkrb2/ mice by transgenic B2R
expression under control of the CMV immediate-early promoter/
enhancer, which directs ubiquitous expression of a transgene [69].
Transgenic Tg-B2R+ mice were generated by pronuclear injection of
the CMV-B2R-eYFP transgene into Bdkrb2/ embryos as described
[57,69]. Radioligand binding and immunoblot detection demon-
strated transgenic B2R protein expression in the aorta of Tg-B2R+
mice whereas B2R binding sites, the B2 receptor protein, and thus
consequently the AT1–B2 receptor heterodimer were absent in the
Tg-B2/ strain (Fig. 2A and B; [69]).
To determine the impact of the B2 receptor on the angiotensin II
AT1R-stimulated vasopressor response, we performed invasive
hemodynamic measurements of transgenic mice with and without
B2 receptor expression. Compared to Tg-B2R+mice with restored B2
receptor protein and identical genetic background, the aortic pressor
response to angiotensin II stimulation of B2 receptor-deﬁcient (Tg-
B2/) mice was signiﬁcantly reduced (Fig. 2C; [69]). Signiﬁcant
differences were observed at angiotensin II doses of 100 ng and
1 mg/kg body weight (Fig. 2C). As a control, the angiotensin II-
stimulated increase in mean arterial pressure (MAP) was mediated
by the AT1 receptor because pre-treatment with the AT1R-speciﬁc
antagonist, losartan, completely blunted the angiotensin II response
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[69]. For comparison, the aortic AT1 receptor number was not
different between Tg-B2/ and Tg-B2R+ mice (91.7  4.1 fmol/mg
and 89.3  3.4 fmol/mg of Tg-B2/ and Tg-B2+ mice, respectively;
n = 5). Thus, B2 receptor deﬁciency and consecutive lack of the AT1–B2
receptor heterodimer were accompanied by a reduced angiotensin II-
stimulated pressor response [69].
These results with Tg-B2/ and Tg-B2R+ mice are complemen-
tary to a previous study, which detected a signiﬁcantly decreased
pressor response of Bdkrb2/ mice after an angiotensin II dose of
5 ng/mouse [70]. In contrast to our study, that study used SVE
S129/J mice as control strain, and analyzed the angiotensin II
pressor response of the femoral artery [70].
The observation that Bdkrb2/mice had a reduced angiotensin
II-stimulated pressor response, was not anticipated [70]. In
contrast, studies with Bdkrb2/ mice largely focussed on the loss
of the B2R-stimulated vasodepressor effect [70,71]. Nevertheless,
our transgenic mouse models with and without B2R expression in
the same genetic background, conﬁrmed previous ﬁndings, i.e. that
individuals with deﬁciency of the vasodepressor B2 receptor and
thus consequently the AT1–B2 receptor heterodimer, showed a
decreased AT1R-mediated vasopressor response compared to Tg-
B2R+ mice with efﬁcient heterodimerization [69,70].
Taken together, data with transgenic mice are compatible with
the concept that upon AT1R–B2R heterodimerization, the B2
receptor enhances angiotensin II AT1R-stimulated G-protein
signaling and thereby supports the AT1R-mediated vasopressor
response (Fig. 2D). That vasopressor-enhancing function of the
B2R–AT1R heteromer complements the well-established vasode-
pressor effects of the bradykinin-stimulated B2R homomer.
7. The AT1–B2 receptor heterodimer as ‘‘novel’’ drug target
7.1. Disruption of the AT1–B2 receptor G-protein interface
Considering the potential pathophysiological relevance, phar-
macological targeting of the AT1R–B2R heterodimer by speciﬁcally
designed ligands is of major interest. Initial experimental
approaches applied site-directed antibodies shielding the intra-
cellular receptor G-protein interface of the B2 receptor located
within the connecting loop between membrane domains III–IV of
the B2 receptor [21,68]. Those antibodies were capable to reduce
the angiotensin II-stimulated G-protein activation of Gaq/11 on
omental vessels of preeclamptic patients [21]. While that approach
provided evidence for the contribution of the AT1–B2 receptor
heterodimer to the angiotensin II hypersensitivity of preeclamptic
vessels [21], the method is not feasible for whole cell or in vivo
studies. Moreover, targeting of the intracellular interface of the B2
receptor is not speciﬁc for the AT1R–B2R heterodimer and could
also interfere with the bradykinin-stimulated G-protein activation
of B2 receptor mono-/homomers. Future research would have to
focus on the identiﬁcation of a heterodimer-speciﬁc contact site to
the G-protein that could be used for the development of a small
molecule inhibitor, which speciﬁcally disrupts the interaction of
AT1R–B2R with the G-protein.
Fig. 2. Decreased AT1R-stimulated vasopressor response in mice lacking the AT1–B2 receptor heterodimer due to targeted deletion of the B2 receptor gene (adapted from Ref.
[69]). (A) Transgenic mice with B2R-eYFP expression under control of the ubiquitous CMV promoter/enhancer (Tg-B2R+) were generated by nuclear injection of the transgene
into embryos from Bdkrb2/mice. Radioligand binding showed comparable number of aortic [3H]bradykinin binding sites of Tg-B2R+ mice and S129/J controls whereas B2R
binding sites were absent in Tg-B2/mice. (B) Immunoblot detection with B2R-speciﬁc antibodies conﬁrmed the absence of the B2 receptor protein on aortic membranes of
Tg-B2/ mice. (C) Angiotensin II (10 ml bolus injection into the jugular vein) caused a smaller increase in mean arterial pressure (MAP) in Tg-B2/ mice than in Tg-B2R+
mice. Data are mean  s.e.m., n = 4 male mice/group, **P < 0.01, ***P < 0.001 (ANOVA and Tukey’s multiple comparison test). (D) Schematic illustration of AT1R–B2R heterodimer
activation by angiotensin II or a biased agonist (Sar1,Ile4,Ile8-AngII). The biased agonist promotes receptor co-internalization but inhibits G-protein activation.
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7.2. A biased angiotensin II AT1 receptor agonist targets the AT1–B2
receptor heterodimer
Recently, another approach to target the AT1–B2 receptor
heterodimer was established. Wilson et al. [25] used an AT1R
ligand, the [Sar1,Ile4,Ile8]-AngII, with biased agonist activity,
which antagonizes the AT1R-stimulated G-protein activation but
promotes AT1R-mediated b-arrestin recruitment, and subsequent
AT1 receptor internalization and b-arrestin-dependent signaling
[72]. The b-arrestin pathway-biased [Sar1,Ile4,Ile8]-AngII was
applied to the AT1–B2 receptor heterodimer of vascular smooth
muscle cells and transfected HEK cells. Stimulation of the AT1–B2
receptor heterodimer with [Sar1,Ile4,Ile8]-AngII promoted not
only AT1 receptor internalization but also B2 receptor co-
internalization [25]. As a consequence, B2 receptor-stimulated
signaling of cells with AT1–B2 receptor heterodimers was
signiﬁcantly reduced whereas [Sar1,Ile4,Ile8]-AngII had no effect
on B2 receptor signaling in the absence of AT1R [25]. Those
ﬁndings are complementary to previous studies, which showed co-
internalization of the AT–B2 receptor heterodimer upon stimula-
tion with angiotensin II or bradykinin [24], and a bradykinin-
stimulated recruitment of b-arrestin to the B2 receptor [57]. Thus,
an AT1R-speciﬁc agonist with biased activity toward b-arrestin
recruitment/signaling concomitantly targets the B2 receptor of the
AT1R–B2R heterodimer (Fig. 2D). Future studies will have to
investigate whether biased agonism for the AT1R–B2R hetero-
dimer could constitute the prototype for a new class of RAAS-
targeting drugs.
8. Outlook
Studies with the AT1R biased agonist, [Sar1,Ile4,Ile8]-AngII,
which stimulates b-arrestin recruitment to the AT1R–B2R
heterodimer and subsequent down-regulation of AT1R–B2R,
demonstrated that pharmacological targeting of the AT1–B2
receptor heterodimer is feasible [25]. Since another member of
that class of biased AT1R agonists is currently in phase II clinical
trial for the treatment of acute heart failure [73], the in vivo role of
the AT1–B2 receptor heterodimer has become a matter of
considerable interest.
Evidence from in vitro and in vivo studies demonstrated
sensitization of the AT1R response by AT1–B2 receptor hetero-
dimerization. That mechanism could contribute to angiotensin II
hypersensitivity under pathophysiological conditions such as
preeclampsia hypertension and other hypertensive conditions.
Transgenic models with deﬁcient AT1R–B2R heterodimerization
due to targeted deletion of the B2R gene compared to transgenic
mice with efﬁcient AT1R–B2R heterodimerization further sup-
ported the concept that the B2 receptor enhances the vascular
AT1R response by heterodimerization.
While those in vitro and in vivo data established a role of the
AT1–B2 receptor heterodimer in sensitizing the AT1R-mediated
vasopressor activity of the vasculature, more investigations are
required to determine the impact of the AT1–B2 receptor
heterodimer on the AT1R response of other relevant organs, e.g.
heart, kidney and brain. Because the B2 receptor is ubiquitously
expressed, additional pathophysiological functions of the AT1–B2
receptor heterodimer can be anticipated, and are suggested by
previous data [68,74]. Notably, conditions of excessive angiotensin
II AT1 receptor stimulation (e.g. hypertension, heart failure,
atherosclerosis) could speciﬁcally promote AT1–B2 receptor
heterodimerization because the B2 receptor is triggered by AT1
receptor-stimulated signaling [75]. Thus, under conditions of
angiotensin II overstimulation, a vicious cycle is suggested
consisting of (i) AT1R-induced B2R up-regulation, (ii) AT1R–B2R
heterodimerization, and (iii) enhanced AT1R-stimulated signaling,
which in turn triggers a new round of B2R up-regulation with
subsequent AT1R–B2R heterodimerization and signal sensitiza-
tion. With the class of biased AT1R agonists as newly established
pharmacological tools, the translation of experimental research on
AT1–B2 receptor heterodimerization to the clinic could be on the
way ahead.
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